Antiangiogenic and Antitumor Efficacy of EphA2 Receptor Antagonist

Cancer Research

Volumn 64, Issue 3, 2004, Pages 910-919

  Dobrzanski, Pawel ^a   Hunter, Kathryn ^a   Jones Bolin, Susan ^a   Chang, Hong ^a   Robinson, Candy ^a   Pritchard, Sonya ^a   Zhao, Hugh ^a   Ruggeri, Bruce ^a  

^a CEPHALON INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5,6,7,13 TETRAHYDRO 12 (3 HYDROXYPROPYL) 9 ISOPROPOXYMETHYLINDENO[2,1 A]PYRROLO[3,4 C]CARBAZOL 5(12H) ONE; ANGIOGENIC FACTOR; BASIC FIBROBLAST GROWTH FACTOR; EPHRIN RECEPTOR A2; EPHRIN RECEPTOR A2 ANTAGONIST; EPHRIN RECEPTOR A2 FC RECEPTOR ANTAGONIST; FC RECEPTOR; MATRIGEL; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ADENOCARCINOMA; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; EX VIVO STUDY; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; LIVER METASTASIS; LYMPH NODE METASTASIS; METASTASIS; MICROVASCULATURE; MOUSE; NONHUMAN; NUDE MOUSE; PANCREAS DUCT; PANCREAS TUMOR; PERITONEUM METASTASIS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR XENOGRAFT; VASCULAR RING;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; AORTA; CARCINOMA, PANCREATIC DUCTAL; FEMALE; HUMANS; MALE; MICE; MICE, NUDE; NEOVASCULARIZATION, PHYSIOLOGIC; PANCREATIC NEOPLASMS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, EPHA2; RECEPTORS, FC; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0842282623     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-3430-2     Document Type: Article

References (44)

1. Carmeliet, P., and Jain, R. K. Angiogenesis in cancer and other diseases. Nature (Lond.), 407: 249-257, 2000.
2. Jung, Y. D., Ahmad, S. A., Akagi, Y., Takahashi, Y., Liu, W., Reinmuth, N., Shaheen, R. M., Fan, F., and Ellis, L. M. Role of the tumor microenvironment in mediating response to anti-angiogenic therapy. Cancer Metastasis Rev., 19: 147-157, 2000.
3. Eberhard, A., Kahlert, S., Goede, V., Hemmerlein, B., Plate, K. H., and Augustin, H. G. Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. Cancer Res., 60: 1388-1393, 2000.
4. Ruggeri, B., Singh, J., Gingrich, D., Angeles, T., Albom, M., Chang, H., et al. CEP-7055: A novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models. Cancer Res., 63: 5978-5991, 2003.
5. Bergers, G., Javaherian, K., Lo, K. M., Folkman, J., and Hanahan, D. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science (Wash. DC), 284: 808-812, 1999.
6. Gale, N. W., and Yancopoulos, G. D. Growth factors acting via endothelial cell-specific receptor tyrosine kinases: VEGFs, angiopoietins, and ephrins in vascular development. Genes Dev., 13: 1055-1066, 1999.
7. Yancopoulos, G. D., Davis, S., Gale, N. W., Rudge, J. S., Wiegand, S. J., and Holash, J. Vascular-specific growth factors and blood vessel formation. Nature (Lond.), 407: 242-248, 2000.
8. Gale, N. W., Holland, S. J., Valenzuela, D. M., Flenniken, A., Pan, L., Ryan, T. E., Henkemeyer, M., Strebhardt, K., Hirai, H., Wilkinson, D. G., Pawson, T., Davis, S., and Yancopoulos, G. D. Eph receptors and ligands comprise two major specificity subclasses and are reciprocally compartmentalized during embryogenesis. Neuron, 17: 9-19, 1996.
9. Wilkinson, D. G. Multiple roles of EPH receptors and ephrins in neural development. Nat. Rev. Neurosci., 2: 155-164, 2001.
10. Holland, S. J., Gale, N. W., Mbamalu, G., Yancopoulos, G. D., Henkemeyer, M., and Pawson, T. Bidirectional signaling through the EPH-family receptor Nuk and its transmembrane ligands. Nature (Lond.), 383: 722-725, 1996.
11. Bruckner, K., Pasquale, E. B., and Klein, R. Tyrosine phosphorylation of transmembrane ligands for Eph receptors. Science (Wash. DC), 275: 1640-1643, 1997.
12. Kullander, K., and Klein, R. Mechanisms and functions of Eph and ephrin signaling. Nat. Rev. Mol. Cell. Biol., 3: 475-486, 2002.
13. Daniel, T. O., Stein, E., Cerretti, D. P., St John, P. L., Robert, B., and Abrahamson, D. R. ELK and LERK-2 in developing kidney and microvascular endothelial assembly. Kidney Int. Suppl., 57: S73-S81, 1996.
14. Pandey, A., Shao, H., Marks, R. M., Polverini, P. J., and Dixit, V. M. Role of B61, the ligand for the Eck receptor tyrosine kinase, in TNF-α-induced angiogenesis. Science (Wash. DC), 268: 567-569, 1995.
15. Wang, H. U., Chen, Z. F., and Anderson, D. J. Molecular distinction angiogenic interaction between embryonic arteries and veins revealed by ephrin-B2 and its receptor Eph-B4. Cell, 93: 741-753, 1998.
16. Gerety, S. S., Wang, H. U., Chen, Z. F., and Anderson, D. J. Symmetrical mutant phenotypes of the receptor EphB4 and its specific transmembrane ligand ephrin-2 in cardiovascular development. Mol. Cell, 4: 403-414, 1999.
17. Adams, R. H., Wilkinson, G. A., Weiss, C., Diella, F., Gale, N. W., Deutsch, U., Risau, W., and Klein, R. Roles of ephrinB ligands and EphB receptors in cardiovascular development: demarcation of arterial/venous domains, vascular morphogenesis, and sprouting angiogenesis. Genes Dev., 13: 295-306, 1999.
18. McBride, J. L., and Ruiz, J. C. Ephrin-A1 is expressed at sites of vascular development in the mouse. Mech. Dev., 77: 201-204, 1998.
19. Huynh-Do, U., Vindis, C., Liu, H., Cerretti, D. P., McGrew, J. T., Enriquez, M., Chen, J., and Daniel, T. O. Ephrin-B1 transduces signals to activate integrin-mediated migration, attachment and angiogenesis. J. Cell Sci., 115: 3073-3081, 2002.
20. Holzman, L. B., Marks, R. M., and Dixit, V. M. A novel immediate-early response gene of endothelium is induced by cytokines and encodes a secreted protein. Mol. Cell. Biol., 10: 5830-5838, 1990.
21. Ogawa, K., Pasqualini, R., Lindberg, R. A., Kain, R., Freeman, A. L., and Pasquale, E. B. The ephrin-A1 ligand and its receptor, EphA2, are expressed tumor neovascularization. Oncogene, 19: 6043-6052, 2000.
22. Brantley, D. M., Cheng, N., Thompson, E. J., Lin, Q., Brekken, R. A., Thorpe, P. E., Muraoka, R. S., Cerretti, D. P., Pozzi, A., Jackson, D., Lin, C., and Chen, J. Soluble Eph A receptors inhibit tumor angiogenesis and progression in vivo. Oncogene, 21: 7011-7026, 2002.
23. Cheng, N., Brantley, D. M., and Chen, J. The ephrins and Eph receptors in angiogenesis. Cytokine Growth Factor Rev., 13: 75-85, 2002.
24. Zelinski, D. P., Zantek, N. D., Stewart, J. C., Irizarry, A. R., and Kinch, M. S. EphA2 overexpression causes tumorigenesis of mammary epithelial cells. Cancer Res., 61: 2301-2306, 2001.
25. Straume, O., and Akslen, L. A. Importance of vascular phenotype by basic fibroblast growth factor, and influence of the angiogenic factors basic fibroblast growth factor/ fibroblast growth factor receptor-1 and ephrin-A1/EphA2 on melanoma progression. Am. J. Pathol., 160: 1009-1019, 2002.
26. Andres, A. C., Reid, H. H., Zurcher, G., Blaschke, R. J., Albrecht, D., and Ziemiecki, A. Expression of two novel eph-related receptor protein tyrosine kinases in mammary gland development and carcinogenesis. Oncogene, 9: 1461-1467, 1994.
27. Zou, J. X., Wang, B., Kalo, M. S., Zisch, A. H., Pasquale, E. B., and Ruoslahti, E. An Eph receptor regulates integrin activity through R-Ras. Proc. Natl. Acad. Sci. USA, 96: 13813-13818, 1999.
28. Miao, H., Burnett, E., Kinch, M., Simon, E., and Wang, B. Activation of EphA2 kinase suppresses integrin function and causes focal-adhesion-kinase dephosphorylation. Nat. Cell Biol., 2: 62-69, 2000.
29. Brown, K. J., Maynes, S. F., Bezos, A., Maguire, D. J., Ford, M. D., and Parish, C. R. A novel in vitro assay for human angiogenesis. Lab. Investig., 75: 539-555, 1996.
30. Nicosia, R. F., Lin, Y. J., Hazelton, D., and Qian, X. Endogenous regulation of angiogenesis in the rat aorta model. Role of vascular endothelial growth factor. Am. J. Pathol., 151: 1379-1386, 1997.
31. Passaniti, A., Taylor, R. M., Pili, R., Guo, Y., Long, P. V., Haney, J. A., Pauly, R. R., Grant, D. S., and Martin, G. R. A simple, quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin, and fibroblast growth factor. Lab. Investig., 67: 519-528, 1992.
32. Pili, R., Robinson, C., Morris, C. A., Dionne, C. A., Isaacs, J. T., and Ruggeri, B. A. CEP-5214, a novel orally-active inhibitor of vascular endothelial growth factor (VEGF) receptor tyrosine kinases, inhibits VEGF-induced angiogenesis and prostate tumor growth in vivo. Clin. Cancer Res., 7: 3658s, 2001.
33. Baker, C. H., Solorzano, C. C., and Fidler, I. J. Blockade of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling for therapy of metastatic human pancreatic cancer. Cancer Res., 62: 1996-2003, 2002.
34. Zhu, W. H., Guo, X., Villaschi, S., and Nicosia, R. F. Regulation of vascular growth and regression by matrix metalloproteinases in the rat aorta model of angiogenesis. Lab. Investig., 80: 545-555, 2000.
35. Stein, E., Lane, A. A., Cerretti, D. P., Schoecklmann, H. O., Schroff, A. D., Van Etten, R. L., and Daniel, T. O. Eph receptors discriminate specific ligand oligomers to determine alternative signaling complexes, attachment, and assembly responses. Genes Dev., 12: 667-678, 1998.
36. Adams, R. H., Diella, F., Hennig, S., Helmbacher, F., Deutsch, U., and Klein, R. The cytoplasmic domain of the ligand ephrinB2 is required for vascular morphogenesis but not cranial neural crest migration. Cell, 104: 57-69, 2001.
37. Relf, M., LeJeune, S., Scott, P. A., Fox, S., Smith, K., Leek, R., Moghaddam, A., Whitehouse, R., Bicknell, R., and Harris, A. L. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor β-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res., 57: 963-969, 1997.
38. Filleur, S., Volpert, O. V., Degeorges, A., Voland, C., Reiher, F., Clezardin, P., Bouck, N., and Cabon, F. In vivo mechanisms by which tumors producing thrombospondin 1 bypass its inhibitory effects. Genes Dev., 15: 1373-1382, 2001.
39. Kerbel, R. S., Yu, J., Tran, J., Man, S., Viloria-Petit, A., Klement, G., Coomber, B. L., and Rak, J. Possible mechanisms of acquired resistance to anti-angiogenic drugs: implications for the use of combination therapy approaches. Cancer Metastasis Rev., 20: 79-86, 2001.
40. Walker-Daniels, J., Coffman, K., Azimi, M., Rhim, J. S., Bostwick, D. G., Snyder, P., Kerns, B. J., Waters, D. J., and Kinch, M. S. Overexpression of the EphA2 tyrosine kinase in prostate cancer. Prostate. 41: 275-280, 1999.
41. Hess, A. R., Seftor, E. A., Gardner, L. M., Carles-Kinch, K., Schneider, G. B., Seftor, R. E., Kinch, M. S., and Hendrix, M. J. Molecular regulation of tumor cell vasculogenic mimicry by tyrosine phosphorylation: role of epithelial cell kinase (Eck/ EphA2). Cancer Res., 61: 3250-3255, 2001.
42. Potla, L., Boghaert, E. R., Armellino, D., Frost, P., and Damle, N. K. Reduced expression of EphrinA1 (EFNA1) inhibits three-dimensional growth of HT29 colon carcinoma cells. Cancer Lett., 175: 187-195, 2002.
43. Zantek, N. D., Azimi, M., Fedor-Chaiken, M., Wang, B., Brackenbury, R., and Kinch, M. S. E-cadherin regulates the function of the EphA2 receptor tyrosine kinase. Cell Growth Differ., 10: 629-638, 1999.
44. Orsulic, S., and Kemler, R. Expression of Eph receptors and ephrins is differentially regulated by E-cadherin. J. Cell Sci., 113: 1793-1802, 2000.